Clinical trials in rare lymphomas

The list below shows The Lymphoma Group's current clinical trials open for recruitment for rare lymphomas such as:

  • Mantle cell lymphoma
  • Burkitt's lymphoma
  • MALToma (Marginal zone) lymphoma
  • CNS (brain) lymphoma
  • Waldenström macroglobulinemia

If you would like to know how to access our trials, please see how to contact us.

  • StepPharma/STP938 - Testing STP938 in people with T-cell and B-cell lymphomas that has relapsed or is refractory
  • MK1026-003 - A trial of MK-1026 for some types of blood cancer, including marginal zone lymphoma, mantle cell lymphoma, Waldenström macroglobulinemia, brain lymphoma and Burkitt's lymphoma
  • BGB-11417-201 - A trial testing BGB-11417 in patients with mantle cell lymphoma that has not responded (refractory) or has come back (relapsed) after previous treatment
  • RAINBOW - Testing both rituximab and ibrutinib versus dexamethasone, rituximab and cyclophosphamide as initial treatment for patients with Waldenström macroglobulinemia
  • OptiMATe - Aims to optimise the MATRix chemotherapy regimen in people with newly diagnosed primary central nervous system (CNS) lymphoma as well as reducing side-effects and improving outcomes
  • PRIZM+ - Testing zanubrutinib in people with relapsed or refractory primary central nervous system (CNS) lymphoma


With special thanks to the following:

Lymphoma ActionCRUKBloodwiseNCRI

For further information on each trial, please visit the Find a trial page on Lymphoma Action’s website.

Last updated: October 2023